TickerTalks
Browse all tickers →
TickerTalks›$CORT
COCORT

Corcept Therapeutics Incorporated

$CORT·$12B·Medical - Pharmaceuticals·Healthcare
$115.70+1.5%YTD+223.5%1Y+61.3%
Price updated 8h ago·X counts updated 8h ago
COCORT
$CORTCorcept Therapeutics Incorporated
$115.70+1.51%73 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $CORT on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

73X posts · last 7 days
Aug 27Sep 9
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $CORT's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 52% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data8 posts analyzed · as of 2026-08-06

Corcept Therapeutics chatter is unambiguously bullish. Q2 diluted EPS $0.36 vs $0.02 est, revenue $256.1M vs $220M est, FY26 guided to $1.1-1.2B revenue. Piper raised PT to $165 from $88 (HCW same to $165 from $95, Canaccord $161 from $150). Stock +25% today (+226% total post-Lifyorli FDA approval); the Trump-family purchase pre-approval is being highlighted. Bulls see Cushing's approval and BELLA trial readout driving $200+. Very little bear voice.

Read what X is saying about $CORT

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $CORT — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Driven by hypeAcceleratingAI verdict · as of 2026-09-08

The move is getting stronger, with heavier trading behind it.

Corcept +212% YTD post-Lifyorli FDA approval — Piper $165, Cushing's and BELLA the next legs.

Corcept Therapeutics is the cortisol-modulator pure-play biotech — the specific way to trade Lifyorli (relacorilant) and Korlym for Cushing's syndrome and beyond. The Q2 print blew away every metric (EPS $0.36 vs $0.02, revenue $256.1M vs $220M) and the stock is +226% post-Lifyorli FDA approval.

Where the trajectory earns its label:

  • The economics are exceptional: 98% gross margin, -1% operating margin (temporary from launch investment), and $1.1-1.2B FY26 revenue guide — those are real drug-launch numbers, and the guide alone justifies the current multiple as a growth trajectory.
  • The analyst-target lifts are simultaneous and material: Piper $165 (from $88), HCW $165 (from $95), Canaccord $161 (from $150) — three-firm target lift the same week is the specific institutional-flow signal that pulls new capital in.
  • The BlackRock $1.08B new investment plus BNY Mellon $49M add is the load-bearing signal: mega-cap institutional deployment at this scale confirms the launch story has institutional cover.

The trajectory holds while Lifyorli launch continues and the BELLA trial readout supports the next leg. A specific launch-execution miss or a competitive Cushing's therapy launch is the reset risk; continued launch beats plus BELLA data extend the trend. The Trump-family-purchase-pre-approval framing is unusual but not the load-bearing signal.

Agrees with X sentimentAgree with the bull framing — the three-firm analyst target lift, BlackRock's $1.08B new position, Q2 crushed print, BELLA readout catalyst, and the FDA-approval-driven +226% history are all substantive anchors. The absence of a bear voice reflects a real drug launch working, not just hype.

What to watch: Watch Lifyorli launch metrics on the next quarterly, BELLA trial readout, and any additional analyst target lifts. A continued launch beat plus positive BELLA data extends the trend; a launch-execution miss is the specific reset trigger.

lifyorli launch rampthree firm target liftblackrock 1b position

Read the AI verdict on $CORT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops and commercializes cortisol modulators including mifepristone (Korlym) for Cushing's syndrome with an expanding oncology pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Pharmaceuticals sits in its cycle right now — and what that implies for $CORT.

Medical - Pharmaceuticals · Healthcare

Specialty pharmaceutical royalty and niche products offer defensive income characteristics; AI-drug-repositioning is an incremental value-add for royalty portfolios. IRA drug-price negotiation is a medium-term overhang on patent-cliff timing.

What this means for $CORT

Partial — Corcept Therapeutics cortisol modulation; Korlym for Cushing's syndrome, mifepristone applications expanding.

Top industry ETF

$XLVHealth Care Select Sector SPDR
+7.9%YTD
+20.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
180.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-1.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-1.1%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
1.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
11.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
7.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
98.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 29, 2026$0.36$0.02+1383.3%
Q1 2026Apr 30, 2026$-0.30$-0.11-172.3%
Q4 2025Feb 24, 2026$0.20$0.33-39.4%
Q3 2025Nov 4, 2025$0.16$0.18-11.1%
Next earningsWed, Nov 4·consensus EPS $0.81

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$164.9M+4.9%98.3%-30.1%$-0.30$-17.0M
Q4 FY25$202.1M+11.1%98.7%2.2%$0.23$38.4M
Q3 FY25$207.6M+13.7%97.8%4.9%$0.19$54.5M
Q2 FY25$194.4M+18.7%98.2%13.7%$0.33$43.9M

Forward consensus

5-year forecast · up to 4 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$1.1B$1.1B – $1.1B$2.06$1.19 – $2.563
FY27$1.6B$1.5B – $1.7B$4.29$2.38 – $5.063
FY28$2.2B$1.8B – $2.8B$7.12$3.72 – $11.634
FY29$2.5B$2.3B – $2.8B$8.54$7.62 – $10.102
FY30$3.1B$2.9B – $3.6B$12.20$10.88 – $14.432

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.89%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+10.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+72.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 90.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.455-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 2Vieira Roberto WandenkolkPresident58.3K sh$6.5MSellSep 1Sean MaduckSee Remarks25.0K sh$2.9MSellAug 26Kimberly ParkDirector26.7K sh$3.3MSellAug 25Sean MaduckSee Remarks31.0K sh$3.9MSellAug 18David L MahoneyDirector103.6K sh$12.3MSellAug 17Robb Gary CharlesChief Business Officer10.0K sh$1.2MSellAug 14Sean MaduckSee Remarks3.7K sh$419KSellAug 14James N WilsonDirector10.0K sh$1.1MSellAug 10Sean MaduckSee Remarks1.0K sh$118KSellAug 10William GuyerChief Development Officer16.3K sh$1.8M
1–10 of 29
+ 55 other (20 exempts · 18 awards · 10 inkinds · 7 gifts) in window

See when $CORT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsSep 33
AI summary

Roberto Wandenkolk Vieira, President of Oncology at Corcept Therapeutics (CORT), filed an initial Form 3 as of September 1, 2026, disclosing 4,068 shares of common stock held directly (including unvested restricted stock awards granted in 2025–2026) plus three tranches of stock options: 200,000 shares at $21.63 (originally 400,000, half already exercised), 140,000 shares at $60.58, and 140,000 shares at $35.70 — all vesting ratably over four years. Routine new-officer Section 16 disclosure; the option grants reflect standard long-term incentive compensation.

8-KPress release / Reg FDJul 298-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

Corcept Therapeutics Incorporated filed an 8-K on July 29, 2026 under Items 2.02 and 7.01 to report its financial results for the second quarter ended June 30, 2026, and to furnish a supplemental disclosure under Regulation FD. The company, a Menlo Park, California-based commercial-stage pharmaceutical company, markets Korlym (mifepristone) for Cushing's syndrome and has a pipeline of selective cortisol modulators in development. The financial results press release is furnished as an exhibit and includes quarterly product revenue, net income, and cash position; detailed figures are in the attached exhibit. Corcept has demonstrated consistent revenue growth from Korlym with a clean balance sheet and investors watch for updates to annual revenue guidance.

8-KOfficer or director changeMay 288-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Corcept Therapeutics held its 2026 Annual Meeting on May 21, 2026. Shareholders elected 8 directors, ratified Ernst & Young LLP as independent auditor, approved advisory executive compensation, and approved an Amendment to the 2024 Incentive Award Plan adding 8,000,000 shares (effective May 21, 2026). The equity plan expansion represents modest incremental dilution to existing shareholders.

8-KPress release / Reg FDApr 308-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

Corcept Therapeutics (CORT) issued a press release on April 30, 2026 announcing Q1 2026 financial results (quarter ended March 31, 2026) and a corporate update, furnished as Exhibit 99.1 and signed by CFO Atabak Mokari. The filing and press release are furnished under Exchange Act Regulation FD and are not filed for Section 18 liability purposes. No specific financial figures are disclosed in the filing body itself.

+ 10 other (3 13Gs · 3 routine 8-Ks · 2 10-Qs · 1 S-8) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Corcept: Not Cheap, But Backed By Real Structural Growthseekingalpha.com·2d agoBank of America Corp DE Grows Holdings in Corcept Therapeutics Incorporated $CORTdefenseworld.net·12d agoWhy Is Corcept (CORT) Down 1.2% Since Last Earnings Report?zacks.com·13d agoBank of New York Mellon Corp Invests $49.19 Million in Corcept Therapeutics Incorporated $CORTdefenseworld.net·13d agoBlackRock Inc. Makes New $1.08 Billion Investment in Corcept Therapeutics Incorporated $CORTdefenseworld.net·19d ago

More in Medical - Pharmaceuticals

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LQDA$RPRX$PAVS
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport